
    
      Primary objective was to assess feasibility and safety; the investigators compared adverse
      events from up to 3months before treatment until up to 12 months after the infusion.

      As a secondary objective, the investigators chose efficacy outcomes to assess the Expanded
      Disability Status (EDSS)„ÄÅannual relapse rate (ARR) and time to next relapse after transplant.

      Third objective anterior visual pathway and pyramidal tract as a model of wider disease.
      Masked endpoint analyses was used for electrophysiological and selected imaging outcomes.
    
  